Background Within a period of three years, we identified 13 patients in whom pure red-cell
aplasia developed during treatment with recombinant human erythropoietin (epoetin). We …

Multiple myeloma (MM) is a plasma cell malignancy preliminary localized in the bone
marrow and characterized by its capacity to disseminate. IL-6 and IGF-1 have been shown to …

Cancer cells require nutrients and energy to adapt to increased biosynthetic activity, and
protein synthesis inhibition downstream of mammalian target of rapamycin complex 1 (mTORC1…

Cancer cells require glutamine to adapt to increased biosynthetic activity. The limiting step
in intracellular glutamine catabolism involves its conversion to glutamate by glutaminase (GA)…

The phosphoinositide 3-kinase (PI3K)/Akt signaling pathway has been shown to be frequently
activated in blast cells from patients with acute myeloid leukemia (AML) and to contribute …

The phosphatidylinositol 3-kinase (PI3K)/Akt and mTORC1 pathways are frequently activated,
representing potential therapeutic targets in acute myeloid leukemia (AML). In 19 AML …

Erythropoietin (Epo) controls the proliferation, differentiation and survival of the erythroid
progenitors. This cytokine was cloned in 1985 and rapidly became used for treatment of anemia …

The mammalian target of rapamycin (mTOR) and the phosphoinositide 3-kinase (PI3K)
signaling pathways are commonly deregulated in cancers and promote cellular growth, …

Finding an effective treatment for acute myeloid leukemia (AML) remains a challenge, and all
cellular processes that are deregulated in AML cells should be considered in the design of …

The deregulation of translation markedly contributes to the malignant phenotype in cancers,
and the assembly of the translation initiating complex eIF4F is the limiting step of this process…